Investigational drug · Phase 2
JNJ-95597528
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dermatitis, Atopic, Asthma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "JNJ-95597528"
First trial start
2026
Jan 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-95597528", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dermatitis, Atopic
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-95597528" as an intervention, largest first.
- A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe AsthmaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07746687 · 440 participants (planned) · Start Oct 5, 2026 · Primary completion Sep 11, 2029
Drug: JNJ-95597528; Placebo · For: Asthma
Sites: Westminster, California; Boston, Massachusetts; Minneapolis, Minnesota · 19 sites in all
- A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07230860 · 189 participants · Start Jan 20, 2026 · Primary completion Nov 19, 2026
Drug: JNJ-95597528; Placebo · For: Dermatitis, Atopic
Sites: Fountain Valley, California; Los Angeles, California; Santa Ana, California · 62 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Dermatitis, Atopic
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CamoteskimabAPL-9109Phase 22 trials
Apollo Therapeutics Ltd · Atopic Dermatitis, Atopic, Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.